Kurome Therapeutics is developing therapies that target cancer cells that have co-opted immune signaling pathways in order to avoid destruction by traditional therapeutic agents and subvert adaptive resistance mechanisms.
Kurome Therapeutics is a preclinical stage company that is developing a series of IRAK1/4, panFLT3 inhibitors. Preclinical studies have demonstrated:
-Broad range of efficacy in MDS and AML patient-derived cell lines
-Synergy with Venclexta® (Venetoclax) to improve Venclexta® potency
-Identification of a biomarker that correlates with prognosis in AML patients and maximal activation of immune signaling through this pathway in AML cells
-Increased overall survival in cell line and patient-derived xenograft models, well beyond that of existing FLT3 inhibitors
-Maintenance of complete efficacy even in settings of adaptive resistance to FLT3 inhibitors and in settings of FLT3 mutations
Kurome Therapeutics is founded on research developed in the laboratory of Dr. Daniel Starczynowski at Cincinnati Children's Hospital Medical Center in collaboration with the National Center for Advancing Translational Sciences (NCATS) at the NIH.
Kurome Therapeutics is a preclinical stage company that is developing a series of IRAK1/4, panFLT3 inhibitors. Preclinical studies have demonstrated:
-Broad range of efficacy in MDS and AML patient-derived cell lines
-Synergy with Venclexta® (Venetoclax) to improve Venclexta® potency
-Identification of a biomarker that correlates with prognosis in AML patients and maximal activation of immune signaling through this pathway in AML cells
-Increased overall survival in cell line and patient-derived xenograft models, well beyond that of existing FLT3 inhibitors
-Maintenance of complete efficacy even in settings of adaptive resistance to FLT3 inhibitors and in settings of FLT3 mutations
Kurome Therapeutics is founded on research developed in the laboratory of Dr. Daniel Starczynowski at Cincinnati Children's Hospital Medical Center in collaboration with the National Center for Advancing Translational Sciences (NCATS) at the NIH.
Location: United States, Ohio, Cincinnati
Employees: 1-10
Total raised: $15M
Founded date: 2019
Investors 1
| Date | Name | Website |
| - | Angel Phys... | angelphysi... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 11.06.2021 | Series A | $15M | - |
Mentions in press and media 7
| Date | Title | Description |
| 11.06.2021 | In DiDi IPO, a one-time rival Uber stands to gain | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox. A few years ago, local ride-hailing upstarts in countries including Southeast Asia and China defe... |
| 11.06.2021 | StartUPDATES: New developments from healthcare startups | HealthMine has created a free resource to help health plans improve their member engagement strategy. The Checklist for Effective Member Engagement contains everything you’ll need to ensure your member engagement initiatives are coordinated... |
| 11.06.2021 | Kurome Therapeutics Closes $15M Series A | CINCINNATI, OH, Kurome Therapeutics has closed a $15 million Series A financing. The round was co-led by Medicxi and Affinity Asset Advisors. >> Click here for more funding data on Kurome Therapeutics >> To export Kurome The... |
| 11.06.2021 | Kurome Therapeutics Closes $15M in Series A Funding | Kurome Therapeutics, a Cincinnati OH-based-developer of therapies that target adaptive resistance mechanisms in cancer, raised $15M in Series A funding. Jan Rosenbaum, Ph.D., chief executive officer and chief scientific officer – CincyTech ... |
| 10.06.2021 | Kurome Therapeutics Closes $15 Million Series A Financing to Develop Targeted Kinase Inhibitors for Treatment of Hematopoietic Cancers | Kurome Therapeutics, a preclinical stage company dedicated to developing novel therapies that target adaptive resistance mechanisms in cancer cells while inhibiting critical disease modifying genes, today announced the closing of a $15 mill... |
| 10.06.2021 | Kurome raises $15M to overcome adaptive resistance in leukemia | Kurome Therapeutics has raised $15 million to treat acute myeloid leukemia (AML) by targeting adaptive resistance mechanisms. Medicxi and Affinity Asset Advisors co-led the series A round to fund Kurome through IND-enabling studies. Cancer ... |
| - | StartUPDATES: New developments from healthcare startups | HealthMine has created a free resource to help health plans improve their member engagement strategy. The Checklist for Effective Member Engagement contains everything you’ll need to ensure your member engagement initiatives are coordinated... |